(Q50479880)

14 March 2018

review article

1 reference

title

Screening out irrelevant cell-based models of disease. (English)

1 reference

14 March 2018

author

María C Montoya

7

1 reference

14 March 2018

Päivi Östling

8

1 reference

14 March 2018

Spencer Shorte

11

1 reference

14 March 2018

Daniel Ebner

Daniel Ebner

6

0 references

Neil O Carragher

Neil O Carragher

14

0 references

Leo S. Price

Leo S Price

10

0 references

Marc Bickle

3

Marc Bickle

1 reference

14 March 2018

author name string

Peter Horvath

1

1 reference

14 March 2018

Nathalie Aulner

2

1 reference

14 March 2018

Anthony M Davies

4

1 reference

14 March 2018

Elaine Del Nery

5

1 reference

14 March 2018

Vilja Pietiäinen

9

1 reference

14 March 2018

Gerardo Turcatti

12

1 reference

14 March 2018

Carina von Schantz

13

1 reference

14 March 2018

publication date

12 September 2016

1 reference

14 March 2018

Nature Reviews Drug Discovery

published in

1 reference

14 March 2018

volume

15

1 reference

14 March 2018

issue

11

1 reference

14 March 2018

page(s)

751-769

1 reference

14 March 2018

https://scigraph.springernature.com/pub.10.1038/nrd.2016.175

exact match

0 references

cites work

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Alzheimer's disease: new approaches to drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Alzheimer's disease: clinical trials and drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Discovery of small molecule cancer drugs: successes, challenges and opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The challenge of emerging and re-emerging infectious diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Emerging viral diseases: confronting threats with new technologies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Trial watch: Phase II failures: 2008-2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Changing medium and passaging cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Maintenace and loss in tissue culture of specific cell characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Dissolved oxygen concentration in culture medium: assumptions and pitfalls.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

What is the appropriate oxygen tension for in vitro culture?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Oxygen matters: tissue culture oxygen levels affect mitochondrial function and structure as well as responses to HIV viroproteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Oxygen concentration modulates the differentiation of muscle stem cells toward myogenic and adipogenic fates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Liver zonation: Novel aspects of its regulation and its impact on homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Microfluidic organs-on-chips.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The role of matrix stiffness in regulating cell behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Tissue cells feel and respond to the stiffness of their substrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Soft biological materials and their impact on cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Mechanochemical manipulation of hepatocyte aggregation can selectively induce or repress liver-specific function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Reconstituting organ-level lung functions on a chip

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Cellular sources of extracellular matrix in hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Involvement of hepatic stellate cell cytoglobin in acute hepatocyte damage through the regulation of CYP2E1-mediated xenobiotic metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The Challenges of Precision Oncology Drug Development and Implementation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Patient-centric trials for therapeutic development in precision oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The role of microenvironment and immunity in drug response in leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Use of reprogrammed cells to identify therapy for respiratory papillomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Prospective derivation of a living organoid biobank of colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Correlating chemical sensitivity and basal gene expression reveals mechanism of action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Multidimensional drug profiling by automated microscopy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High-content phenotypic profiling of drug response signatures across distinct cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Pluripotent stem cells in disease modelling and drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A non-inheritable maternal Cas9-based multiple-gene editing system in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Mammalian Synthetic Biology: Time for Big MACs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Rewriting the blueprint of life by synthetic genomics and genome engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Human iPSC-based modeling of late-onset disease via progerin-induced aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Development of high content imaging methods for cell death detection in human pluripotent stem cell-derived cardiomyocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A chemical screen identifies novel compounds that overcome glial-mediated inhibition of neuronal regeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

An open-access microfluidic model for lung-specific functional studies at an air-liquid interface

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Induced pluripotent stem cells from a spinal muscular atrophy patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Evolution of strategies to improve preclinical cardiac safety testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Self-organizing human cardiac microchambers mediated by geometric confinement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Development of a drug screening platform based on engineered heart tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Muscle on a chip: in vitro contractility assays for smooth and striated muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Cyclic stretch of embryonic cardiomyocytes increases proliferation, growth, and expression while repressing Tgf-β signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Generation of stem cell-derived β-cells from patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

iPSC-derived β cells model diabetes due to glucokinase deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Muscular dystrophy in a dish: engineered human skeletal muscle mimetics for disease modeling and drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Induced pluripotent stem cells: at the heart of cardiovascular precision medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Multiplex genome engineering using CRISPR/Cas systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

CRISPR-Cas systems for editing, regulating and targeting genomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Imaging genomic elements in living cells using CRISPR/Cas9.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Genome-scale CRISPR-Cas9 knockout screening in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High-throughput functional genomics using CRISPR-Cas9.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Genetic screens in human cells using the CRISPR-Cas9 system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A new age in functional genomics using CRISPR/Cas9 in arrayed library screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Genome editing of human pluripotent stem cells to generate human cellular disease models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Genetic Modification in Human Pluripotent Stem Cells by Homologous Recombination and CRISPR/Cas9 System

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The impact of CRISPR-Cas9 on target identification and validation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

CRISPR-mediated direct mutation of cancer genes in the mouse liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The development of a 3D immunocompetent model of human skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A novel 3D high-content assay identifies compounds that prevent fibroblast invasion into tissue surrogates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Bioartificial matrices for therapeutic vascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Hybrid printing of mechanically and biologically improved constructs for cartilage tissue engineering applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Fabrication of PEGylated Fibrinogen: A Versatile Injectable Hydrogel Biomaterial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Immunocompetent 3D model of human upper airway for disease modeling and in vitro drug evaluation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Assay optimization: a statistical design of experiments approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Comparison of genetic algorithms for experimental multi-objective optimization on the example of medium design for cyanobacteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Overcoming obstacles in the implementation of factorial design for assay optimization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Tissue-culture light sheet fluorescence microscopy (TC-LSFM) allows long-term imaging of three-dimensional cell cultures under controlled conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Pancreatic cancer organotypic cultures.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Variability in vascular smooth muscle cell stretch-induced responses in 2D culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A microfluidic shear device that accommodates parallel high and low stress zones within the same culturing chamber

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Microfluidically supported biochip design for culture of endothelial cell layers with improved perfusion conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Optimization of microfluidic single cell trapping for long-term on-chip culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arrays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Integrated microfluidic bioprocessor for single-cell gene expression analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Droplet microfluidic technology for single-cell high-throughput screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The beautiful cell: high-content screening in drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Live cell in vitro and in vivo imaging applications: accelerating drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Integration of multiple readouts into the z' factor for assay quality assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Label-free cytotoxicity screening assay by digital holographic microscopy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Digital holographic microscopy: a quantitative label-free microscopy technique for phenotypic screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

DIC image reconstruction using an energy minimization framework to visualize optical path length distribution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

BioImageXD: an open, general-purpose and high-throughput image-processing platform.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Ultra high content image analysis and phenotype profiling of 3D cultured micro-tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Systems pharmacology: network analysis to identify multiscale mechanisms of drug action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Distinctive Behaviors of Druggable Proteins in Cellular Networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

canSAR: updated cancer research and drug discovery knowledgebase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Computation as the mechanistic bridge between precision medicine and systems therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Medusa: A tool for exploring and clustering biological networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Systematic identification of genomic markers of drug sensitivity in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Inconsistency in large pharmacogenomic studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Pharmacogenomic agreement between two cancer cell line data sets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Enhancing reproducibility in cancer drug screening: how do we move forward?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Developing predictive assays: the phenotypic screening "rule of 3".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Development of a quantitative 96-well method to image glycogen storage in primary rat hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Accurate prediction of drug-induced liver injury using stem cell-derived populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Therapeutic targeting of integrin αvβ6 in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Preclinical target validation using patient-derived cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A novel multiple-stage antimalarial agent that inhibits protein synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Can laboratory reference strains mirror "real-world" pathogenesis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Bacterial quorum sensing in pathogenic relationships

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The distributed genome hypothesis as a rubric for understanding evolution in situ during chronic bacterial biofilm infectious processes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Chemical genetics of Plasmodium falciparum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Culture of skin cells in 3D rather than 2D improves their ability to survive exposure to cytotoxic agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Micro 3D cell culture systems for cellular behavior studies: Culture matrices, devices, substrates, and in-situ sensing methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Microfluidic 3D cell culture: from tools to tissue models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

From 3D cell culture to organs-on-chips

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The third dimension bridges the gap between cell culture and live tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Three-Dimensional Cell Culture Assays: Are They More Predictive of In Vivo Efficacy than 2D Monolayer Cell-Based Assays?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Bioprinting for cancer research.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

3D bioprinting of tissues and organs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Three-dimensional organotypic culture: experimental models of mammalian biology and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Life in 3D is never flat: 3D models to optimise drug delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Constructive remodeling of a synthetic endothelial extracellular matrix

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A review of microfabrication and hydrogel engineering for micro-organs on chips

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Synthetic 3D multicellular systems for drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Materials science. Hydrogel cell cultures.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Peptide Hydrogels - Versatile Matrices for 3D Cell Culture in Cancer Medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Cell adhesion on an artificial extracellular matrix using aptamer-functionalized PEG hydrogels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Three-dimensional tissue culture based on magnetic cell levitation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Nanomagnetic levitation three-dimensional cultures of breast and colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Microfluidic compartmentalized co-culture platform for CNS axon myelination research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

How were new medicines discovered?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Phenotypic screening in cancer drug discovery - past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

The discovery of first-in-class drugs: origins and evolution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Micro and nano-scale in vitro 3D culture system for cardiac stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

HB-EGF affects astrocyte morphology, proliferation, differentiation, and the expression of intermediate filament proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Designing cell-compatible hydrogels for biomedical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

A microfabricated scaffold induces the spheroid formation of human bone marrow-derived mesenchymal progenitor cells and promotes efficient adipogenic differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Microfluidics for cell-based high throughput screening platforms - A review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Organs-on-chips at the frontiers of drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Tissue models: a living system on a chip.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.175

Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).

31 March 2020

1 reference

12 December 2020

In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

1 reference

12 December 2020

Cell culture, oxidative stress, and antioxidants: avoiding pitfalls

1 reference

12 December 2020

Imaging cellular spheroids with a single (selective) plane illumination microscope

1 reference

12 December 2020

Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells.

1 reference

12 December 2020

Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates

1 reference

12 December 2020

Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.175

1 reference

14 March 2018

PubMed ID

27616293

1 reference

14 March 2018